Regentis Biomaterials Ltd.
AMEXRegentis Biomaterials reports today after a month of persistent selling, entering the print as one of the more visibly distressed small-cap biotech names on the AMEX. The stock is down 18% over the past month and shed another 11% on Monday alone, closing at $2.55. That follows a 15% weekly decline and a year-to-date drop approaching 57%. Short interest has been easing — shares…
Snapshot as of 7 May 2026
Regentis Biomaterials reports today after a month of persistent selling, entering the print as one of the more visibly distressed small-cap biotech names on the AMEX. The stock is down 18% over the past month and shed…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RGNT — free to start on ORTEX.
Sign up for free →Open RGNT on ORTEX